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Abstract
Background: Observational studies rarely account for confounding by indication, whereby empiric antibiotics
initiated for signs and symptoms of infection prior to the diagnosis of infection are then viewed as risk factors for
infection. We evaluated whether confounding by indication impacts antimicrobial risk factors for methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) acquisition.
Findings: We previously reported several predictors of MRSA and VRE acquisition in 967 intensive care unit (ICU)
patients with no prior history of MRSA or VRE who had an initial negative screening culture followed by either a
subsequent negative screening culture (controls) or positive screening or clinical culture (cases). Within and prior to this
acquisition interval, we collected demographic, comorbidity, daily device and antibiotic utilization data. We now
re-evaluate all antibiotics by medical record review for evidence of treatment for signs and symptoms ultimately
attributable to MRSA or VRE. Generalized linear mixed models are used to assess variables associated with MRSA or
VRE acquisition, accounting for clustering by ward. We find that exclusion of empiric antibiotics given for suspected
infection affects 17% (113/661) of antibiotic prescriptions in 25% (60/244) of MRSA-positive patients but only 1%
(5/491) of antibiotic prescriptions in 1% (3/227) of VRE-positive patients. In multivariate testing, fluoroquinolones are no
longer associated with MRSA acquisition, and aminoglycosides are significantly protective (OR=0.3, CI:0.1-0.7).
Conclusions: Neglecting treatment indication may cause common empiric antibiotics to appear spuriously associated
with MRSA acquisition. This effect is absent for VRE, likely because empiric therapy is infrequent given the low
prevalence of VRE.
Keywords: Antimicrobial predictors, MRSA, VRE, Confounding by indication
Findings
Background
MRSA and VRE are important causes of hospital morbid-
ity and mortality [1,2]. Colonization with either pathogen
confers substantial risks of subsequent infection. Within
18 months after acquisition, up to 33% of MRSA carriers
and 8% of VRE carriers develop invasive disease, with
post-discharge infections often requiring readmission
[3,4]. These high risks of infection have fueled efforts to
identify modifiable risk factors for acquisition. Several
risk factors for MRSA and VRE acquisition are well-known
including prolonged hospitalization, invasive devices, sur-
gery, and environmental contamination [5-8]. Other modi-
fiable risk factors commonly include recent treatment with
antibiotics. Numerous case–control studies, including our
own, have shown a significant association between patho-
gen acquisition and fluoroquinolones, cephalosporins, and
other antibiotics [9-13].
However, none of these studies accounted for confound-
ing by indication [9-13], an unrecognized yet common
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tion occurs when the effects of treatment indication are
ignored, or in general, when factors that may be a conse-
quence of a condition are instead treated as potential
causes of that condition [14,15]. In this setting, confound-
ing by indication may occur when empiric antibiotics are
prescribed for signs and symptoms of an MRSA or VRE
infection prior to the diagnosis of infection, and then the
same antibiotics are viewed as risk factors for the infec-
tion. In such cases antibiotics represent a consequence of
infection, rather than a potential cause.
Studies evaluating antibiotic exposures prior to culture
confirmation of MRSA or VRE may falsely assume that an-
tibiotics predict acquisition when, in actuality, they may
have been given empirically for infectious symptoms related
to MRSA or VRE. For example, pneumonia in an ICU pa-
tient with no prior history of MRSA may be treated with
levofloxacin and vancomycin. If clinical cultures ordered
days later demonstrate MRSA, assessments may spuriously
conclude that both antibiotics are associated with acquisi-
tion since treatment preceded the MRSA-positive culture
dates. In this study, we sought to assess whether the exclu-
sion of antibiotics initiated for suspected infection ultim-
ately attributed to MRSA or VRE changed antimicrobial
risk factors for acquisition.
Methods
We previously reported several factors, including antibi-
otics, associated with MRSA and VRE acquisition in a
case–control study of 967 ICU patients from a 750-bed
tertiary care center in Boston, Massachusetts between
September 2003 and April 2005 [12]. For this article,
we re-examined antibiotic exposures and determined
whether antibiotics were initiated for signs and symp-
toms of an infection later attributed to MRSA or VRE.
This study was approved by the Institutional Review Board
at Brigham and Women’sH o s p i t a l .
Study procedures were described previously [12]. Briefly,
we identified all patients with no prior history of MRSA
who had an initial negative screening culture followed by
either a subsequent negative screening culture (controls)
or a positive screening or clinical culture (cases). From
this cohort, we selected all cases and a random sample of
controls for MRSA and a separate random sample of con-
trols for VRE cases at a 1:1 ratio. There was no minimal
ICU time requirement for cases and controls, and screen-
ing reflected high-compliance admission and weekly sur-
veillance nares cultures for MRSA and rectal cultures for
VRE. Within and prior to this eligible interval for acqui-
sition, we collected multiple variables including dia-
betes, end-stage renal disease, chronic liver disease, solid
and hematologic malignancies, time from ICU admission
to initial negative screening culture, wounds, rashes, sur-
gery, intubation, bronchoscopy, central lines, drains, tubes,
albumin and creatinine levels, colonization pressure, and
the presence of antibiotic-susceptible strains. Colonization
pressure of MRSA (or VRE) was defined as the sum
of daily number of same ward MRSA-positive (or
VRE-positive) patients to which patients were exposed
during the eligible interval for acquisition and catego-
rized as follows: 0, 1-<4, 4-<8, 8-<12, and ≥12. Time
from ICU admission to initial negative screening swab
was also categorized (1 day, 2 days, and ≥3d a y s ) .
All antibiotics were re-evaluated by medical record re-
view for evidence of treatment for symptoms ultimately
attributable to MRSA or VRE. Antibiotic administration
was assessed for the time period encompassing two weeks
prior to the initial negative surveillance culture until the
time of subsequent negative or positive surveillance or clin-
ical culture. Antibiotics were classified as follows: narrow-
spectrum penicillins, broad-spectrum penicillins; first,
second and third-generation cephalosporins; fluoroquino-
lones; carbapenems; aminoglycosides; macrolides; anti-
MRSA (vancomycin, linezolid, synercid, daptomycin,
tigecycline); and anti-VRE (linezolid, synercid, daptomy-
cin, tigecycline) antibiotics. All antibiotics initiated empir-
ically for signs and symptoms later attributed to MRSA or
VRE infection were reviewed and confirmed by an infec-
tious diseases physician. Antibiotics given for co-infection
with another pathogen were retained.
Statistical methods
The association between antibiotics and acquisition was
first assessed using bivariate models. Variables with p<0.1
were entered into multivariable logistic regression models.
Final models were constructed by retaining variables with
p<0.05 in the multivariable models [12]. Bivariate and
multivariable assessments accounted for clustering by
ICU ward using generalized linear mixed models logistic
regression. All analyses were conducted using SAS 9.3
(SAS Institute, Cary, NC).
Results
We identified 244 cases and 248 controls for MRSA and
227 cases and 248 controls for VRE during the study
period. Patient characteristics have been summarized pre-
viously [12]. Briefly, MRSA and VRE groups were similar,
with 52% >65 years-old, 25% with solid cancers, and 82%
undergoing surgery.
Exclusion of empiric antibiotics given for signs and symp-
toms ultimately due to infection affected 17% (113/661) of
antibiotic prescriptions among MRSA-positive patients but
only 1% (5/491) of antibiotic prescriptions among VRE-
positive patients. The most commonly affected antibiotics
among MRSA-positive patients included anti-MRSA anti-
biotics (41 exclusions of 182 prescriptions), fluoroquino-
lones (30 exclusions of 193 prescriptions), third-generation
cephalosporins (25 exclusions of 63 prescriptions),
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clindamycin (4 exclusions of 18 prescriptions). No second-
generation cephalosporins or broad-spectrum penicillins
were prescribed for symptoms later attributed to MRSA
infections. In the VRE group, few patients experienced in-
fection, and thus very few antibiotics were attributable to
signs or symptoms of infection. Only 1 aminoglycoside, 1
fluoroquinolone, and 3 third-generation cephalosporin
prescriptions were excluded. Overall, accounting for treat-
ment indication impacted 25% (60/244) of MRSA-positive
patients and 1% (3/227) of VRE-positive patients.
Exclusion of antibiotics initiated empirically for signs
and symptoms ultimately due to MRSA affected risk fac-
tors for acquisition (Table 1). Fluoroquinolones were no
longer associated with acquisition, and aminoglycosides
were found to be significantly protective (OR=0.3, CI:0.1-
0.7). This effect persisted when forcing fluoroquinolone
prescriptions into the model excluding antibiotics ini-
tiated empirically for suspected MRSA infection (fluoro-
quinolones OR= 1.1, CI:0.7-1.7; aminoglycosides OR =0.3,
CI:0.1-0.7). Risk factors for VRE acquisition were not ree-
valuated due to the minimal impact of antibiotic exclusion.
Discussion
When identifying predictors of MRSA acquisition, failure
to account for treatment indication caused common em-
piric antibiotics to appear falsely associated with MRSA
acquisition. Such confounding has not been addressed
in published case–control studies [9-13] and may occur
when empiric antibiotics pre-date MRSA cultures that de-
fine acquisition. In future studies, investigators should ad-
dress the possibility of confounding by indication in data
analysis and interpretation.
Several hospital studies report that MRSA carriage is
associated with fluoroquinolones [9,11-13,16], an em-
piric agent commonly prescribed for infections requiring
hospitalization. However, we note that this artifactual as-
sociation frequently occurs with other empiric antibi-
otics. In our data, approximately 25% of prescriptions
for fluoroquinolones, third-generation cephalosporins,
aminoglycosides and anti-MRSA antibiotics were ex-
cluded after accounting for treatment indication. These
findings are consistent with the use of fluoroquinolones
as a common first-line agent for empiric therapy at our
institution during the study period. After excluding em-
piric antibiotics used for suspected MRSA infection,
fluoroquinolones were no longer associated with MRSA.
In addition, aminoglycosides were found to be signifi-
cantly protective of acquisition, a plausible finding given
its activity against many MRSA isolates [17].
In contrast to MRSA, confounding by indication was
infrequent for VRE. This finding is likely due to the low
prevalence of VRE infection in our ICU population des-
pite oncology and transplant services in our hospital
[2,4]. Thus, accounting for treatment indication had no
impact on antimicrobial risk factors for VRE.
This work has important limitations. First, this ICU
study from a large tertiary care center may lack
generalizability. Second, these data were often reliant on
single-site screening cultures to determine negative car-
riage status. However, all patients had no prior history of
carriage based on microbiology records dating back to
1987 [12]. Third, extranasal MRSA carriage and multiple
VRE rectal screens were not assessed to corroborate ac-
quisition. Thus, results may not apply to clones that
colonize non-surveillance sites.
In conclusion, we show that neglecting treatment indi-
cation may cause common empiric antibiotics to appear
falsely associated with MRSA acquisition. These findings
are relevant to the common practice of conducting
retrospective cohort and case–control studies to deter-
mine antimicrobial risk factors for acquisition of multi-
Table 1 Variables associated with methicillin-resistant Staphylococcus aureus acquisition before and after accounting
for confounding by indication
Variable Odds ratio (95% CI), P Value
Before accounting for
confounding by indication
a
After accounting for
confounding by indication
Methicillin-sensitive S. aureus carrier 0.5 (0.3, 1.0), 0.03 0.4 (0.2, 0.8), 0.01
Intubation 4.7 (1.8, 12.3), 0.002 5.3 (2.0, 14.4), 0.001
Fluoroquinolone 1.9 (1.2, 3.0), 0.01 -
Aminoglycoside - 0.3 (0.1, 0.7), 0.003
Days from ICU admission to negative swab < .0001 <.0001
1 1.0, reference 1.0, reference
2 2.0 (1.2, 3.3) 2.2 (1.3, 3.7)
≥3 15.6 (8.4, 29.0) 19.6 (10.4, 37.1)
Chronic liver disease - 4.1 (1.2, 13.6), 0.02
aPreviously reported elsewhere [12].
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such as fluoroquinolones may spuriously appear to in-
crease the risk of pathogen acquisition if treatment indica-
tion is ignored. Readers should use caution in interpreting
assessments of antibiotic exposures for conditions often
treated with antibiotics.
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